Recombinant IL‐1 ligands (marketed as Dainippon/Immunex [IL‐1α] and Syntex [IL‐1β]) were administered to cancer patients with the most common symptoms being flu‐like symptoms including fever, chills, rigors and nausea.17 Here, IL1A is linked to cancer.